Csl enters licensing agreement with arcturus therapeutics for next generation mrna vaccine technology

King of prussia, pa. , nov. 1, 2022 /prnewswire/ -- csl limited (asx:csl; usotc:cslly) today announces that its subsidiary, csl seqirus, has entered into a collaboration and license agreement with arcturus therapeutics holdings inc ("arcturus therapeutics") to access their late stage self-amplifying mrna (sa-mrna) vaccine platform technology.
ARCT Ratings Summary
ARCT Quant Ranking